The DNA-testing company is exploring its options, including a business combination and the sale of some or all of its assets.

Me is considering a sale of the company as it weighs up strategic options, capping a torrid year for the genetic testing ...

Me (ME), the company that popularized consumer genetic testing, announced Tuesday that it is once again exploring “strategic ...

Shares in 23andMe are currently trading at around $3.40, giving it a valuation of just under $82 million. The company went ...

The struggling genetic-testing 23andMe is looking for a buyer for the virtual-care business it acquired in 2021, Business ...

By the 2023 fiscal year, 23andMe had reported a net loss of $312 million and its individual share price has plummeted a ...

Me (ME) forms special board committee to explore strategic alternatives, including sale, restructuring, or business ...

The latest unsurprising development in 23andMe’s story is the admission, by their new board of directors, that 23andMe now does not have enough cash to continue for the next 12 months. They are now ...

23andMe said it's started exploring strategic alternatives, including a possible sale. The company released third-quarter ...

Em­bat­tled ge­net­ics test­ing gi­ant 23andMe is think­ing of sell­ing it­self as it runs out of cash. The com­pa­ny needs ...

The testing company ended last year with $79 million and told investors it will need to raise money to fund its operations ...

23andMe has been exploring a possible sale of its telehealth business, Business Insider has learned. The struggling health company bought the virtual-care startup Lemonaid in 2021 for $400 million.